Bruker winds down underperforming instrument lines


Instrument heavyweight Bruker is winding down its range of stand-alone gas chromatography (GC), inductively-coupled plasma mass spectrometry (ICP-MS) and single quadrupole GC-MS instruments. In a statement, the company said that its Chemical and Applied Markets division, which houses these products, has generated significant losses for the last four years, with little prospect of near-term profitability.

Bruker will honour outstanding orders for the affected GC and GC-MS instruments, but is not taking any new orders. The company is looking to sell off its ICP-MS business, and for someone to take over the service contracts for the GC instruments. The firm will retain support for GC-MS systems, as it continues to sell instruments with triple-quadrupole mass detectors.

At the same time, the company is expanding its microscopy offering in the life sciences, by acquiring US start-up Vutara for its high speed, 3D, super resolution fluorescence microscopy technology. The companies did not disclose financial details of the transaction.


Related Content

X marks the structure

31 October 2014 Review

news image

Elisabeth Jeffries discovers there’s a diffractometer for everything from crystals to proteins

A close look at microscopy

5 November 2013 Review

news image

Elisabeth Jeffries zooms in on scanning probe microscopy and other techniques

Most Read

Complex amines made easy (and cheap)

22 May 2015 Research

news image

Iron-catalysed cross-coupling brings together nitroarenes and olefins in a single step in boon for drug makers

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers